ALCL

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
星期一, 五月 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

Origin Bancorp, Inc. Reports Earnings for First Quarter 2024

Retrieved on: 
星期三, 四月 24, 2024
Sale, BTH, MSR, Total, Central Time, FHLB, News, Tier 2, Insurance, Conference, Webcast, Environment, OBK, Tax, ALCL, Growth, Cryptocurrency

We recorded a credit loss provision of $3.0 million during the quarter ended March 31, 2024, compared to $2.7 million in the linked quarter.

Key Points: 
  • We recorded a credit loss provision of $3.0 million during the quarter ended March 31, 2024, compared to $2.7 million in the linked quarter.
  • Nonperforming LHFI increased $10.3 million for the quarter, and nonperforming LHFI to LHFI increased over the past quarter to 0.51% compared to 0.39% for the linked quarter.
  • Noninterest income for the quarter ended March 31, 2024, was $17.3 million, an increase of $9.1 million, or 110.5%, from the linked quarter.
  • Origin will hold a conference call to discuss its first quarter 2024 results on Thursday, April 25, 2024, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期二, 三月 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Origin Bancorp, Inc. Reports Earnings for Second Quarter 2023

Retrieved on: 
星期三, 七月 26, 2023
Lender option borrower option, Insurance, National Student Loan Data System, FHLB, Tax, ALCL, FDIC, Central Time, Sale, PPP, Baozou Big News Events, OBK, SBA, Webcast, Conference, News, Total, Security (finance), Cryptocurrency, Real estate, Bank, Rare-earth element

The Company recorded a credit loss provision of $4.3 million during the quarter ended June 30, 2023, compared to $6.2 million recorded during the linked quarter.

Key Points: 
  • The Company recorded a credit loss provision of $4.3 million during the quarter ended June 30, 2023, compared to $6.2 million recorded during the linked quarter.
  • Classified loans decreased $1.9 million at June 30, 2023, compared to the linked quarter, and represented 1.11% of LHFI at June 30, 2023, compared to 1.17% at March 31, 2023.
  • Noninterest income for the quarter ended June 30, 2023, was $15.6 million, a decrease of $748,000, or 4.6%, from the linked quarter.
  • Origin will hold a conference call to discuss its second quarter 2023 results on Thursday, July 27, 2023, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Origin Bancorp, Inc. Reports Earnings for First Quarter 2023

Retrieved on: 
星期三, 四月 26, 2023
Lender option borrower option, Insurance, National Student Loan Data System, Maintenance, BTH, FHLB, Tax, ALCL, AFS, Central Time, Sale, PPP, ATM, Baozou Big News Events, SBA, Webcast, Conference, News, Total, Security (finance), Video game, Cryptocurrency, Airline, Real estate, Bank

The Company recorded a credit loss provision of $6.2 million during the quarter ended March 31, 2023, compared to $4.6 million recorded during the linked quarter.

Key Points: 
  • The Company recorded a credit loss provision of $6.2 million during the quarter ended March 31, 2023, compared to $4.6 million recorded during the linked quarter.
  • Net charge-offs to total average LHFI (annualized) increased to 0.07% for the quarter ending March 31, 2023, compared to 0.01% for the linked quarter.
  • Noninterest income for the quarter ended March 31, 2023, was $16.4 million, an increase of $3.0 million, or 22.0%, from the linked quarter.
  • Origin will hold a conference call to discuss its first quarter 2023 results on Thursday, April 27, 2023, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
星期二, 三月 28, 2023
Communication, ASH, PD, Head, Atopic dermatitis, Time management, B-cell lymphoma, Patient, Ipilimumab, HIV/AIDS research, Lymphoma, ITK, Lung cancer, UCSF, FDA, Autoimmunity, Safety, PR, Total, AACR, ALC, Cancer, T-cell lymphoma, NSCLC, Immunotherapy, PFS, University, Blood, PTCL-NOS, Chart, Kidney cancer, CR, Webcast, Research, Pembrolizumab, Call, HIV, RCC, KCRC, Clinical trial, ALCL, PET, Fungal infection, Toxic epidermal necrolysis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, SD, Food, Nivolumab, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, Conference, Corvus

BURLINGAME, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.
  • The findings of the human and preclinical studies suggest that CPI-818 enhances anti-tumor immunity representing a potentially novel approach to immunotherapy.
  • In the fourth quarter of 2022, the decrease of $0.7 million was primarily related to a decrease in personnel costs.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2022 financial results.

Origin Bancorp, Inc. Reports Earnings for Fourth Quarter and 2022 Full Year

Retrieved on: 
星期三, 一月 25, 2023
Policy, Marketing, Insurance, Tax, News, FHLB, ALCL, Advertising, MSR, BTH, Webcast, Conference, AFS, Sale, SBA, Baozou Big News Events, Day 1, Total, National Student Loan Data System, CECL, PPP, Growth, Exercise, GNMA, Lender option borrower option, Central Time, Security (finance), Renewable energy, Bank, Airline, Lease, Video game, Life insurance, Real estate

Net charge-offs to total average LHFI (annualized) decreased to 0.01% for the quarter ending December 31, 2022, compared to 0.07% for the quarter ending September 30, 2022.

Key Points: 
  • Net charge-offs to total average LHFI (annualized) decreased to 0.01% for the quarter ending December 31, 2022, compared to 0.07% for the quarter ending September 30, 2022.
  • Classified loans increased $4.4 million at December 31, 2022, compared to the linked quarter, and represented 1.05% of LHFI, at December 31, 2022, compared to 1.01% at September 30, 2022.
  • Noninterest income for the quarter ended December 31, 2022, was $13.4 million, a decrease of $294,000, or 2.1%, from the linked quarter.
  • Average FHLB advances were $511.9 million for the quarter ended December 31, 2022, a decrease of $12.0 million from $523.9 million for the quarter ended September 30, 2022.

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Patient, ORR, Angioimmunoblastic T-cell lymphoma, Company, Progression-free survival, Fatigue, B-cell lymphoma, Therapy, Risk, III/IV, PM, Society, PRS, Peripheral T-cell lymphoma, NDAS, Safety, IND, Time in China, GemOx, ASH, Relapse, SEHK, PFS, Extranodal NK/T-cell lymphoma, nasal type, Nature, CEO, NDA, LAUNCH, CR, Nausea, Greater, Annual report, Hematology, Vomiting, Genta (company), Hong Kong Stock Exchange, ET, ALCL, Natural killer cell, SDS, Time, Phases of clinical research, PTCL-NOS, Fine chemical, Pharmaceutical industry, Dexamethasone

SHANGHAI and HONG KONG, Nov. 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will present updated results from the Phase Ib TOUCH study of selinexor for treatment of R/R T and NK-cell lymphoma in a poster at the upcoming 2022 American Society of Hematology (ASH) Annual Meeting. In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract. The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.

Key Points: 
  • In addition, preliminary results from the investigator-initiated LAUNCH trial will be published in an on-line abstract.
  • The 2022 ASH Annual Meeting will be held virtually and in person in New Orleans, Louisiana, the United States, from December 10-13, 2022.
  • "The data to be presented at ASH 2022 highlights the broad clinical potential and manageable side effect profile of selinexor in patients with well-defined T-cell lymphomas and R/R MM," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • "It is our great pleasureto share these updates with the hematology/oncology community at ASH 2022."

Global Osimertinib Drugs Market Report 2022: Relatively Low Risk of Side Effects Compared to Other Drugs Driving Adoption - ResearchAndMarkets.com

Retrieved on: 
星期五, 十一月 4, 2022
Pharmaceutical, Health, Oncology, Awareness, Growth, Hospital, CAGR, Region, Radiation, Squamous cell carcinoma, Prescription, NSCLC, Neoplasm, Application, Tablet, Large-cell lung carcinoma, ALCL, Risk, Cancer, Lung cancer, Pneumonectomy, Estimation, Patient, Pharmaceutical industry, Medical imaging, Health insurance, Osimertinib

The "Global Osimertinib Drugs Market: by Type by Application and by Region - Forecast and Estimation for 2017-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Osimertinib Drugs Market: by Type by Application and by Region - Forecast and Estimation for 2017-2027" report has been added to ResearchAndMarkets.com's offering.
  • Global Osimertinib drugs market is expected to reach US$ 11,839.8 million by 2027 at a CAGR of 16.1%, from US$ 4828.6 million in 2021, according to a new report.
  • In recent years, the demand for Osimertinib drugs has grown rapidly due to the positive clinical results seen in cancer patients.
  • Osimertinib has a relatively low risk of side effects when compared to other treatments available to patients.

Secura Bio Announces Final Patient Enrolled in the COPIKTRA® (duvelisib) (PRIMO) Study in Relapsed and Refractory Peripheral T-cell Lymphoma

Retrieved on: 
星期三, 二月 9, 2022
Enzyme, Maintenance, Growth, Cohort, Colitis, Peripheral T-cell lymphoma, CR, Rash, ALCL, Toxicity, DOR, Sepsis, Infection, Neutropenia, PTCL, Patient, Safety, Survival, ORR, Adult, Pharmacokinetics, National Comprehensive Cancer Network, Population, Lymphocyte, CEO, ASH, Physician, PD, Sustenance, IRC, Diarrhea, PI3K, Society, AST, T-cell lymphoma, Pharmaceutical industry

COPIKTRA monotherapy has received Fast Track status for the treatment of PTCL patients who have received at least one prior therapy.

Key Points: 
  • COPIKTRA monotherapy has received Fast Track status for the treatment of PTCL patients who have received at least one prior therapy.
  • The PRIMO study is a global, multi-center, open-label, parallel cohort, Phase 2 study.
  • The study is ongoing and is expected to have enough events for the primary endpoint analysis later in 2022.
  • COPIKTRA is indicated inthe United Statesfor the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.